Sichuan Biokin received China NMPA clearance to start clinical trials of [177Lu]‑BL‑ARC001, marking continued regulatory activity in radioligand therapy (RLT). Separately, a review of RLT in gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) highlights the modality’s growing role in targeted oncology, summarizing mechanisms, clinical outcomes and the push to broaden indications. The Biokin clearance adds an Asia‑based development program to an RLT landscape dominated by lutetium‑based agents and underlines regional investment in radiopharmaceutical pipelines and manufacturing capacity.